Previous Close | 4.1700 |
Open | 4.2681 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 4.0400 - 4.2681 |
52 Week Range | 1.6900 - 5.4500 |
Volume | |
Avg. Volume | 24,704 |
Market Cap | 634.615M |
Beta (5Y Monthly) | 1.54 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.6700 |
Earnings Date | Aug 30, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.30 |
Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two in
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Opthea Limited (OPT) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Reserve slashed interest rates by a half point in September, kickstarting […]